The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 1.63 — grey zone — between safe and distressedWatch
- Earnings-manipulation signal · Beneish M -3.09 — no flag raisedOK
- Earnings quality 87/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Jazz Pharmaceuticals plc reports it. History and quarterly detail are in the app.
- Product sales, net$4.0B
- Royalties and contract revenues$245.7M
- High-sodium oxybate AG royalty revenue$211.7M
- Other royalty and contract revenues$34.0M
Leadership changes
From Jazz Pharmaceuticals plc's own filings, the day they're filed.
- Anne O'Riordan · director · departureeff. 2026-05-25
- Ted Love · director · appointmenteff. 2025-12-01
- Kenneth W. O'Keefe · Directors · departureeff. 2025-12-01
Latest filings
- DEF 14A · Annual proxy (pay & governance)2026-06-08
- 8-K · Company announcement2026-05-29
- 10-Q · Quarterly report2026-05-05
- 8-K · Company announcement2026-05-05
- 10-K · Annual report2026-02-24
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Jazz Pharmaceuticals plc, every answer cited🔒
- The Intelligence Brief — added when Jazz Pharmaceuticals plc's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.